Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

PWRM, NTRS, IDRA, SA, UEIC- Hot Stock Alerts! from CRWEfinance.com

crwefinancelogo2

signup3m

 

Power3 Medical Products, Inc. (OTC:PWRM)

PWRM, a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, has filed several patent applications for its NuroPro technology that are currently pending. PWRM also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. To date, PWRM has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China, and has published 6 articles in peer-reviewed scientific journals on the subject. PWRM intends to publish these latest findings as well.

PWRM, a bio-technology company, engages in the development and marketing of diagnostic tests in the fields of cancer, and neurodegenerative and neuromuscular diseases in the United States. PWRM’s products include BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer; and NuroPro, a serum test for the detection of neurodegenerative diseases, such as amyotrophic lateral sclerosis, Alzheimer’s disease, and Parkinson’s disease. PWRM’s products analyze proteins and their mutations to assess an individual’s risk for developing disease later in life or a patient’s likelihood of responding to a particular drug; assess a patient’s risk of disease progression and disease recurrence; and measure a patient’s exposure to drug therapy. PWRM was formerly known as Surgical Safety Products, Inc. and changed its name to Power3 Medical Products, Inc. in September 2003. PWRM was founded in 1992 and is based in The Woodlands, Texas.

PWRM recently delivered four poster presentations at the 2010 International Conference on Alzheimer’s Disease (NASDAQ:ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro®, PWRM’s diagnostic test, and focused on PWRM’s Alzheimer’s disease blood serum biomarkers, test and clinical validation trials.

PWRM’s website: www.Power3Medical.com

Universal Electronics Inc. (NASDAQ:UEIC) will host a conference call at 4:30 p.m. ET, Thursday, November 4, 2010 to discuss its third quarter 2010 earnings results.

Management will review the quarterly activity as well as answer questions.

**********

Northern Trust Corporation (Nasdaq:NTRS) reported third quarter net income per common share of $.64, compared with net income per common share of $.77 in the third quarter of 2009 and $.82 per common share in the second quarter of 2010. Net income was $155.6 million in the current quarter, compared with net income of $187.9 million in the prior year’s third quarter and $199.6 million in the second quarter of 2010. Return on average common equity was 9.2% in the current quarter, compared to 11.9% in the prior year’s third quarter and 12.2% in the second quarter.

Earnings per share in the third quarter of 2009 and the second quarter of 2010 each benefited from reductions of an indemnification liability related to Visa, Inc. (Visa).

The associated pre-tax expense reductions totaled $17.8 million ($11.2 million after tax, or $.05 per common share) in the third quarter of 2009 and $12.7 million ($8.0 million after tax, or $0.04 per common share) in the second quarter of 2010.

**********

Idera Pharmaceuticals, Inc. (Nasdaq:IDRA) reported results from its single-dose, dose-escalation Phase 1 clinical trial evaluating the safety and mechanism of action of IMO-3100, its lead Toll-like Receptor (NYSEMKT:TLR) 7 and TLR9 antagonist drug candidate for the treatment of autoimmune and inflammatory diseases.

In the trial, IMO-3100 was well tolerated at all dose levels evaluated in the 30 healthy subjects that received IMO-3100, and target engagement of TLR7 and TLR9 was observed through inhibition of TLR7- and TLR9-mediated immune responses.

The presentation entitled “Safety and Pharmacodynamics of IMO-3100, a Novel Toll-like Receptor Antagonist for Autoimmune and Inflammatory Diseases, in a Rising Single-Dose Phase 1 Clinical Trial” was made today at the 6th Annual Meeting of the Oligonucleotide Therapeutic Society being held in Dana Point, California.

**********

Eleven more core holes drilled this season by Seabridge (AMEX:SA) at its 100% owned Courageous Lake gold project continue to increase confidence in the current resource, moving it towards reserve status. These results are also likely to add to the multi-million ounce resource and increase its overall grade. In total, 44 holes will be drilled this season at Courageous Lake (22,300 meters). Assay results have now been released for the first 22 holes (see also the News Release dated August 5, 2010). The Courageous Lake project is located in Canada's Northwest Territories.

Seabridge President Rudi Fronk noted that "our 2008 Preliminary Assessment on Courageous Lake demonstrated that the FAT deposit has outstanding economic potential at current gold prices. The issue is to upgrade the deposit's large inferred resource. We have now drilled 22 consecutive holes this summer containing significant widths of gold mineralization well above the resource cut-off grade. It is increasingly clear to us that most of the Courageous Lake resource should qualify as reserves in our Preliminary Feasibility Study scheduled

 

********************************************************************

http://crwefinance.com/img/crwefinance_new_buscard2.jpg

Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM)